This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Volpara Health Technologies Beheer

Beheer criteriumcontroles 3/4

De CEO Volpara Health Technologies is Teri Thomas, benoemd in Apr2022, heeft een ambtstermijn van 2.08 jaar. De totale jaarlijkse vergoeding van { bedraagt NZ$ 631.01K, bestaande uit 63.6% salaris en 36.4% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.072% van de aandelen van het bedrijf, ter waarde A$ 208.40K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.8 jaar en 5.3 jaar.

Belangrijke informatie

Teri Thomas

Algemeen directeur

NZ$631.0k

Totale compensatie

Percentage CEO-salaris	63.6%
Dienstverband CEO	2.1yrs
Eigendom CEO	0.07%
Management gemiddelde ambtstermijn	3.8yrs
Gemiddelde ambtstermijn bestuur	5.3yrs

Recente managementupdates

Recent updates

What Volpara Health Technologies Limited's (ASX:VHT) 52% Share Price Gain Is Not Telling You

Dec 19

We're Hopeful That Volpara Health Technologies (ASX:VHT) Will Use Its Cash Wisely

Mar 06

Calculating The Intrinsic Value Of Volpara Health Technologies Limited (ASX:VHT)

Jun 03

Does Volpara Health Technologies (ASX:VHT) Have A Healthy Balance Sheet?

Mar 24

Volpara Health Technologies (ASX:VHT) Shareholders Booked A 93% Gain In The Last Three Years

Jan 28

Volpara Health Technologies (ASX:VHT) Is Using Debt Safely

Dec 24

Here's What We Think About Volpara Health Technologies' (ASX:VHT) CEO Pay

Nov 19

Analyse CEO-vergoeding

Hoe is Teri Thomas's beloning veranderd ten opzichte van Volpara Health Technologies's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2023	n/a	n/a	-NZ$9m
Jun 30 2023	n/a	n/a	-NZ$9m
Mar 31 2023	NZ$631k	NZ$401k	-NZ$10m

Compensatie versus markt: De totale vergoeding ($USD 384.67K ) Teri } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de Australian markt ($USD 674.99K ).

Compensatie versus inkomsten: Er zijn onvoldoende gegevens om de beloning van Teri te vergelijken met de prestaties van het bedrijf.

CEO

Teri Thomas

2.1yrs

Tenure

NZ$631,006

Compensatie

Ms. Teri Jo Thomas is Chief Executive Officer of Volpara Health Technologies Limited from April 2022 and serves as its Managing Director and Director since October 1, 2022. She served as an Executive Vice...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Teri Thomas	CEO, MD & Director	2.1yrs	NZ$631.01k	0.072% A$ 208.4k
Craig Hadfield	CFO & Company Secretary	7.2yrs	NZ$549.27k	geen gegevens
Nico Karssemeijer	Co-Founder & Member of Scientific Board	no data	geen gegevens	0.71% A$ 2.1m
Tana Isaac	Executive Vice President of Product & Technology	1.8yrs	geen gegevens	geen gegevens
Gareth Beaumont	Chief Information Officer & Chief Information Security Officer	4.4yrs	geen gegevens	geen gegevens
Frederik Struve	Joint Company Secretary & General Counsel	2.7yrs	geen gegevens	geen gegevens
Jill Spear	Executive Vice President of Sales & Customer	2.9yrs	geen gegevens	geen gegevens
Kathryn Greene	Chief People Officer	4.9yrs	geen gegevens	geen gegevens
Julian Marshall	Chief Knowledge Officer	no data	NZ$510.51k	geen gegevens
Mark Morris	Executive Vice President	4.4yrs	geen gegevens	geen gegevens
Matt Prickett	Senior Vice President of Product	no data	geen gegevens	geen gegevens
Katherine Singson	Chief Executive Officer of Volpara Solutions Inc	3.8yrs	geen gegevens	geen gegevens

3.8yrs

Gemiddelde duur

Ervaren management: Het managementteam van VHT wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.8 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Teri Thomas	CEO, MD & Director	1.6yrs	NZ$631.01k	0.072% A$ 208.4k
Nico Karssemeijer	Co-Founder & Member of Scientific Board	no data	geen gegevens	0.71% A$ 2.1m
Roger Allen	Non-Executive Director	13.9yrs	NZ$89.54k	7.26% A$ 21.1m
Martin Yaffe	Member of Scientific Board	no data	geen gegevens	0.77% A$ 2.3m
John Pavlidis	Independent Non-Executive Director	9.3yrs	NZ$146.42k	0.027% A$ 79.1k
Ann Custin	Independent Non-Executive Director	2.7yrs	NZ$182.12k	geen gegevens
Bruce Schroeder	Member of Medical Advisory Board	no data	geen gegevens	geen gegevens
Kiyoshi Namba	Member of Medical Advisory Board	no data	geen gegevens	geen gegevens
Jennifer Harvey	Member of Medical Advisory Board	no data	geen gegevens	geen gegevens
Gerard den Heeten	Member of Medical Advisory Board	no data	geen gegevens	geen gegevens
Karin Lindgren	Independent Non-Executive Director	4.3yrs	NZ$162.00k	geen gegevens
Paul Robert Reid	Independent Non-Executive Chairman of the Board	6.2yrs	NZ$121.79k	0.045% A$ 131.7k

5.3yrs

Gemiddelde duur

Ervaren bestuur: De raad van bestuur van VHT wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.3 jaar).

This company listing is no longer active

Volpara Health Technologies Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Volpara Health Technologies Limited Appoints Craig Hadfield Joins as Chief Financial Officer

Volpara Health Technologies Limited, Annual General Meeting, Aug 17, 2023

Volpara Health Technologies Limited Appoints Mark Bouw as Independent, Non-Executive Director

Volpara Health Technologies Limited Appoints Fred Struve as Joint Company Secretary

Volpara Health Technologies Limited Announces the Appointment of Teri Thomas as Managing Director

Key Executive recently bought AU$67k worth of stock

Recent updates

Volpara Health Technologies Limited Appoints Craig Hadfield Joins as Chief Financial Officer

Price target decreased by 7.7% to AU$0.92

Volpara Health Technologies Limited Launches MQSA Compliance Software at the Society for Breast Imaging Symposium

Price target decreased by 13% to AU$1.00

What Volpara Health Technologies Limited's (ASX:VHT) 52% Share Price Gain Is Not Telling You

Lunit Inc. (KOSDAQ:A328130) agreed to acquire Volpara Health Technologies Limited (ASX:VHT) from Harbour Asset Management Limited and others for AUD300 million.

Price target increased by 14% to AU$1.15

First half 2024 earnings released: NZ$0.017 loss per share (vs NZ$0.021 loss in 1H 2023)

Price target decreased by 16% to AU$1.01

Forecast breakeven date pushed back to 2026

New major risk - Revenue and earnings growth

Volpara Health Technologies Limited to Report Q2, 2024 Results on Oct 17, 2023

An Unknown buyer acquired 4% stake in Reveal DX fromVolpara Health Technologies Limited (ASX:VHT).

Volpara Health Technologies Limited, Annual General Meeting, Aug 17, 2023

Volpara Health Technologies Limited to Report Q1, 2024 Results on Jul 21, 2023

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates fall by 137%, revenue upgraded

We're Hopeful That Volpara Health Technologies (ASX:VHT) Will Use Its Cash Wisely

Volpara Health Technologies Limited Appoints Mark Bouw as Independent, Non-Executive Director

Forecast breakeven date pushed back to 2025

First half 2023 earnings released: NZ$0.02 loss per share (vs NZ$0.034 loss in 1H 2022)

Volpara Health Technologies Limited Provides Revenue Guidance for the Full Year 2023

Forecast breakeven date moved forward to 2024

Consensus estimates of losses per share improve by 14%

Forecast breakeven date moved forward to 2024

Volpara Health Technologies Limited Appoints Fred Struve as Joint Company Secretary

Forecast to breakeven in 2025

Volpara Health Technologies Limited Announces the Appointment of Teri Thomas as Managing Director

Volpara Health Launches Professional Services to Accelerate Success for High-Risk Cancer Programs

Forecast breakeven date pushed back to 2025

Key Executive recently bought AU$67k worth of stock

Now 23% undervalued after recent price drop

Price target decreased to AU$1.15

Forecast breakeven date pushed back to 2025

Forecast breakeven date pushed back to 2025

Volpara Health Announces Chief Executive Officer Changes

No longer forecast to breakeven

Price target decreased to AU$1.62

No longer forecast to breakeven

First half 2022 earnings: EPS and revenues exceed analyst expectations

No longer forecast to breakeven

Price target increased to AU$2.00

Non-Executive Director Monica Saini has left the company

Price target decreased to AU$1.74

Volpara Grows Patent Collection with Recently Granted European Protection of Image Quantification

Insider recently sold AU$122k worth of stock

Calculating The Intrinsic Value Of Volpara Health Technologies Limited (ASX:VHT)

Consensus EPS estimates fall to -NZ$0.046

Forecast breakeven pushed back to 2024

Full year 2021 earnings released: NZ$0.07 loss per share (vs NZ$0.097 loss in FY 2020)

Price target decreased to AU$1.84

Price target increased to AU$1.99

Does Volpara Health Technologies (ASX:VHT) Have A Healthy Balance Sheet?

Volpara Health Technologies Signs Highest Value Contract to Date Via CRA Health

New 90-day low: AU$1.30

Volpara Health Technologies Limited (ASX:VHT) acquired CRA Health Services, Inc. for $22 million.

Price target raised to AU$1.81

New 90-day high: AU$1.54

Volpara Health Technologies (ASX:VHT) Shareholders Booked A 93% Gain In The Last Three Years

Volpara Health Technologies Limited to Report Q3, 2021 Results on Jan 28, 2021

Volpara Health Technologies (ASX:VHT) Is Using Debt Safely

Volpara Health Technologies Advises Major Customer Contract It Renewed and Extended in Second Quarter of Fiscal 2021 Is with the US Radiology Group

First half 2021 earnings released: NZ$0.036 loss per share

Here's What We Think About Volpara Health Technologies' (ASX:VHT) CEO Pay

Volpara Health Technologies Announces the Launch of BreastED

New 90-day high: AU$1.47

New 90-day low: AU$1.27

Volpara Health Technologies Limited to Report Q1, 2021 Results on Jul 28, 2020